Clinically Actionable Tumor-Associated Antigens in Prostate Cancer

1. Study Type This is a single-center, observational cohort study incorporating both retrospective and prospective components. It is a non-interventional study that does not involve assignment of participants to specific interventions.
2. Objectives

Primary Objectives:

1. To determine the protein expression profile (positive rate, expression level) of 15 membrane targets (PSMA, B7-H3, STEAP1, TROP2, KLK2, HER2, TF, HER3, DLL3, SEZ6, STEAP2, MUC1, NECTIN4, FAP, PDL1) in diverse clinicopathological subtypes of prostate cancer (HSPC and CRPC，primary and metastatic lesions include lymph node, bone and visceral metastasis, etc.).
2. To characterize the molecular subtypes of prostate cancer based on the expression profiles of AR, PSA, PSMA, Syn, CgA, CD56, p53, RB1, and PTEN across different disease states and metastatic sites.
3. To validate the association between the expression of prognostically significant targets (identified in the retrospective cohort) and overall survival (OS) in an independent, prospectively enrolled cohort of prostate cancer patients.

Secondary Objectives:

1. To compare the expression of each target between matched CSPC and mCRPC samples from the same patients.
2. To compare the expression of each target across different metastatic sites (e.g., bone, lymph node, viscera) in mCRPC.
3. To analyze the association between target expression and clinical outcomes [biochemical recurrence-free survival (BFS), metastasis-free survival (MFS)] in patients with CSPC.
4. To explore co-expression patterns of the targets and their correlation with clinicopathological features.

3.Study Design

Retrospective Cohort:

Population: Patients treated at Peking University First Hospital between 2000-2025.

Cohort 1: Primary Tumor Cohort - This cohort includes patients with CSPC or CRPC, or those with special pathological structures, for whom primary tumor tissue (from biopsy or surgery) is available.

Cohort 2: Lymph Node Metastasis Cohort - This cohort includes patients with CSPC or CRPC for whom lymph node metastasis tissue is available (from biopsy or surgery) .

Cohort 3: Bone Metastasis Cohort - This cohort includes patients with CSPC or CRPC, for whom bone metastasis tissue is available (from biopsy or surgery).

Cohort 4: Visceral Metastasis Cohort - This cohort includes patients with CSPC or CRPC, for whom visceral (e.g., liver, lung) metastasis tissue is available.

Procedures: Archived FFPE tissue blocks will be retrieved for immunohistochemistry (IHC) staining. Clinical and follow-up data will be extracted from medical records.

Prospective Cohort:

Population: Newly diagnosed metastatic prostate cancer patients at Peking University First Hospital from January 1, 2026.

Cohort 5: Prospective Validation Cohort - This cohort will consist of patients with metastatic prostate cancer (mHSPC or mCRPC), from whom tissue samples will be collected prospectively along with their clinical data.

Procedures: Eligible patients will provide informed consent. Residual tumor tissue obtained during standard-of-care biopsies or surgeries will be collected for IHC staining. Patients will be followed prospectively at defined intervals to collect treatment and outcome data.

4.Methods Laboratory Assessment (for both cohorts): IHC will be performed on FFPE tissue sections using validated antibodies against the eight targets (as specified in the protocol: e.g., HER2: ab2142275; TROP2: ab214488; etc.). Staining will be evaluated by pathologists blinded to clinical outcomes. IHC score 0-3,0=negative/none,1=weak,2=moderate,3=strong. A modified H-score ([1×% weak staining + 2×% moderate staining + 3×% strong staining], range 0-300) will be used for quantification.

Data Collection: Clinical data (demographics, laboratory assessment (tPSA、LDH levels)，imaging data(ultrasound, MRI, CT, PET, providing TNM staging results, treatment history, pathology reports) and outcome data (biochemical recurrence, metastasis, death) will be collected retrospectively from databases/records for the retrospective cohort and prospectively during follow-up visits for the prospective cohort.